Stockscreener 앱 받기
0.7588
3.82%
0.0279
전일 마감가:
$0.7309
열려 있는:
$0.72
하루 거래량:
76,719
Relative Volume:
0.13
시가총액:
$18.88M
수익:
$411.00K
순이익/손실:
$-4.85M
주가수익비율:
-1.7245
EPS:
-0.44
순현금흐름:
$-4.88M
1주 성능:
+1.72%
1개월 성능:
-9.67%
6개월 성능:
-12.78%
1년 성능:
-61.58%
1일 변동 폭
$0.6991
$0.76
1주일 범위
$0.6513
$0.81
52주 변동 폭
$0.46
$2.0405
Lexaria Bioscience Corp Stock (LEXX) Company Profile
명칭
Lexaria Bioscience Corp
전화
250-765-6424
주소
100 - 740 MCCURDY ROAD, KELOWNA
LEXX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
0.7588 | 18.19M | 411.00K | -4.85M | -4.88M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Lexaria Bioscience Corp 주식(LEXX)의 최신 뉴스
Pullback Watch: Can COOP stock double in the next yearMarket Movement Recap & Weekly Stock Breakout Alerts - baoquankhu1.vn
Aug Big Picture: What hedge funds are buying Lexaria Bioscience CorpEarnings Growth Report & Stock Portfolio Risk Management - baoquankhu1.vn
Market Leaders: Can Lexaria Bioscience Corp ride the EV waveWeekly Loss Report & Consistent Growth Stock Picks - baoquankhu1.vn
Published on: 2026-01-15 23:22:36 - baoquankhu1.vn
Levels Update: What are Lexaria Bioscience Corp. Equity Warrant’s earnings expectationsMarket Movers & Verified Momentum Stock Alerts - baoquankhu1.vn
Lexaria Bioscience Corp. SEC 10-Q Report - TradingView — Track All Markets
Institution Moves: Is Lexaria Bioscience Corp stock a bargain at current levels2025 Valuation Update & Real-Time Buy Signal Notifications - Bộ Nội Vụ
Lexaria’s DehydraTECH shows reduced side effects in GLP-1 drugs By Investing.com - Investing.com Nigeria
Lexaria Deepens GLP-1 Focus With DehydraTECH Advances, Patents and Fresh Capital - TipRanks
Lexaria Bioscience (LEXX) Advances Oral Drug Delivery with Dehyd - GuruFocus
Lexaria Releases Annual Letter from the CEO - Investing News Network
Lexaria Bioscience CEO Releases Annual Letter, Outlook for 2026 - Intellectia AI
Lexaria Bioscience Shares Rise After Reaching GLP-1 Study Milestone - MSN
Lexaria’s DehydraTECH-semaglutide cuts GLP-1 side effects in phase 1b trial and extends cash runway into 2026 - MSN
Will Lexaria Bioscience Corp. Equity Warrant stock maintain dividend yieldJuly 2025 Setups & Community Verified Trade Signals - Улправда
Is Lexaria Bioscience Corp. Equity Warrant stock dividend yield sustainableJuly 2025 Action & Expert Approved Momentum Trade Ideas - Улправда
Why Lexaria Bioscience Corp. stock is seen as undervaluedTrade Analysis Summary & Community Supported Trade Ideas - ulpravda.ru
What catalysts could drive Lexaria Bioscience Corp. Equity Warrant stock higherJuly 2025 Fed Impact & Safe Capital Growth Stock Tips - Улправда
Why Lexaria Bioscience Corp. Equity Warrant stock could be next big winnerJuly 2025 Macro Moves & Verified Chart Pattern Trade Signals - Улправда
San Gabriel Valley Tribune - FinancialContent
Lexaria Bioscience Corp.Common Stock (NQ: LEXX - FinancialContent
Growth Value: Is Lexaria Bioscience Corp Equity Warrant stock dividend yield sustainable2025 Key Lessons & Technical Pattern Based Buy Signals - moha.gov.vn
Lexaria Bioscience (LEXX) Expected to Announce Earnings on Friday - Defense World
Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4 - New Castle News
Lexaria releases additional results from Phase 1b study GLP-1-H24-4 - Yahoo Finance
Lexaria’s Phase 1b GLP-1 Study Shows Comparable Metabolic Outcomes and Encouraging Blood Pressure Data for DehydraTECH Platform - TipRanks
Lexaria Bioscience (LEXX) Reports Promising Results from Phase 1 - GuruFocus
Drug trial in overweight patients ties CBD formula to lower blood pressure - Stock Titan
Lexaria Bioscience (NASDAQ:LEXX) Shares Up 5.5% – Here’s What Happened - Defense World
Sentiment Review: Is Lexaria Bioscience Corp Equity Warrant stock dividend yield sustainableMarket Performance Report & Stepwise Trade Execution Plans - moha.gov.vn
How geopolitical tensions affect Lexaria Bioscience Corp stock2025 Market Sentiment & Verified Entry Point Signals - moha.gov.vn
Lexaria Bioscience secures $3.5 million in direct offering to boost R&D - MSN
Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday - Benzinga
Lexaria Bioscience stock soars after ending $5M stock sale agreement with JonesTrading - MSN
Lexaria Bioscience stock price target cut to $1.50 from $4 at H.C. Wainwright By Investing.com - Investing.com South Africa
Lexaria Bioscience stock price target cut to $1.50 from $4 at H.C. Wainwright - Investing.com
LEXX: HC Wainwright & Co. Lowers Price Target to $1.50, Maintains Buy Rating | LEXX Stock News - GuruFocus
LEXX: DehydraTECH Formulation Reduces GLP-1 Agonist Side Effects - Research Tree
Primary Endpoint Successfully Achieved in Lexaria’s Phase 1b Study GLP-1-H24-4 - York Dispatch
Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus - Benzinga
Lexaria’s DehydraTECH-Semaglutide Cuts GLP-1 Side Effects in Phase 1b Trial and Extends Cash Runway Into 2026 - TipRanks
Lexaria Bioscience Corp (LEXX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):